Cellectar Biosciences, Inc. cotiza a 1.43 USD y tiene una capitalización bursátil de $14M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for …
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-1.33 | $-0.53 | $-1.41 |
| Estimado | $-0.52 | $-1.88 | $-1.23 | $-2.53 |
| Sorpresa | — | +29.3% | +56.9% | +44.3% |
| Métrica | CLRB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -255.3% | -40.4% | -214.8% |
| ROA | -145.5% | -32.0% | -113.5% |
| Current Ratio | 2.96 | 2.84 | +0.12 |
| Debt / Equity | — | 0.28 | — |